G/TBT/N/GTM/106: Guatemala Notifies a New Regulation for Medicines and Related Products

1. Key takeaways

On 11 February 2026, Guatemala notified G/TBT/N/GTM/106, the “Reglamento para el Control Sanitario de los Medicamentos y Productos Afines” (Regulation for the Sanitary Management and Control of Medicines and Related Products) to the WTO. The notified document runs to 70 pages in Spanish, with a proposed adoption date of 2026-06-01, a proposed entry-into-force date of 2026-12-01, and a comment deadline of 2026-04-12. The statement of purpose and rationale in the notification expressly records that the regulation repeals Acuerdo Gubernativo 712-99 of the President of the Republic. Three implications follow for companies active in Guatemala. First, the regulatory base that has supported registration since 1999 is scheduled for replacement, so every document that cites 712-99 as its legal basis will need re-mapping. Second, the scope of the notified regulation reaches related products, which is the category that includes medical devices. Third, the proposal is still at the notification stage, so all dates and contents remain as notified until the official gazette publishes the final text.

2. Legal basis

The table below summarises the notification record for G/TBT/N/GTM/106 as transmitted to the WTO. All entries are taken from the notification itself; the final published regulation may differ, and the official gazette remains the authoritative source once the text is adopted.

3. Expert insights

Insight 1: This is the first wholesale replacement of the regulatory base since 1999. 712-99 has been in force since 1999-09-17 and is the empowering source for a series of technical standards including NT 37 (issued under its Articles 70, 71 and 72) and NT 40 (issued under its Articles 4, 42, 48, 71 and 72). When the base is replaced, the upstream empowerment chain must be re-aligned, and the downstream technical standards will most likely undergo a round of revision or reissuance. Planning should assume that every citation of 712-99 in internal dossiers will eventually need updating.

Insight 2: The phrase “entire life cycle” deserves close attention. The notification summary states that the regulation establishes principles to guarantee the products’ qualities “en todo su ciclo de vida, incluyendo desde los ensayos clínicos hasta la monitorización” (the entire life cycle, from clinical trials to surveillance). This wording extends the regulatory horizon from the pre-market stage into the post-market stage, standing in contrast with the current absence of a device vigilance chapter in NT 37 — the new regulation may fill this gap.

Insight 3: The proposed entry-into-force date is less than two months away. Counting from the verification date of 2026-10-29, roughly 33 days remain until the proposed date of 2026-12-01. Projects in the pipeline need to decide which set of rules applies: submissions filed before the entry-into-force date follow the current framework, submissions after it follow the new regulation, and projects in between should confirm transitional arrangements with the DRCPFA in advance rather than assume continuity.

Insight 4: The product codes point to medicines, but the scope of the regulation goes far beyond them. The SAC codes in the notification are 30.03 and 30.04 (medicines), yet the content summary expressly includes related products — and devices in Guatemala are precisely classified as related products (productos afines). The regulation therefore has a substantive impact on the device field, and it must not be disregarded on the basis of the tariff headings alone.

Insight 5: The comment period has closed, but the final text has not yet been obtained. The comment period closed on 2026-04-12. As of this verification date, this series has obtained only the WTO notification-level information, not the full regulation as published in the official gazette. This article therefore uses the wording “proposed entry into force”, and the specific provisions are subject to the official gazette.

4. Practical recommendations

• Set 2026-12-01 as a critical milestone in project scheduling and decide which set of rules applies to each pipeline project.
• Establish a monitoring mechanism for the official gazette so that the final text and the transitional provisions are obtained as soon as they appear.
• Map the technical standard bases of existing registrations in advance and estimate the re-alignment workload after the upstream law is replaced.
• Watch whether the new regulation introduces device vigilance and life-cycle surveillance provisions, and prepare the corresponding capabilities ahead of time.
• Complete whatever submissions can be completed before the entry-into-force date, and avoid placing critical milestones inside the transition period.

5. Verification checklist

• □ Notification number G/TBT/N/GTM/106 and notification date 2026-02-11 recorded
• □ Proposed adoption 2026-06-01 and proposed entry into force 2026-12-01 recorded
• □ Repeal target recorded as Acuerdo Gubernativo 712-99
• □ Official gazette monitoring mechanism established
• □ Technical standard bases of existing registrations mapped
• □ Applicable rules decided for each pipeline project

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com